Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

EAST HANOVER, N.J., March 19, 2012 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta™ Neohaler™ (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not indicated to treat asthma. It is also not indicated to treat acute deteriorations of COPD and should not be used as a rescue medication for acute symptoms.

Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist (LABA) approved in the US for maintenance treatment of airflow obstruction in patients with COPD. Arcapta Neohaler is an inhaled, steroid-free COPD treatment.

Arcapta Neohaler 75 mcg was studied in a total of 641 COPD patients in two key Phase III trials lasting 12 weeks. The primary endpoint results at week 12 showed that Arcapta Neohaler significantly improved lung function (FEV1) at 24 hours compared to placebo. As a secondary endpoint, lung function (FEV1) improvements were seen at five minutes after the first dose compared to placebo, and improvements observed at week 4 were consistently maintained over the course of 12 weeks in both trials.

"Arcapta Neohaler represents an important new treatment option for the 14 million Americans living with COPD," said Andre Wyss, President, Novartis Pharmaceuticals Corporation. "The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market."

COPD is a common, preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways of the lungs to noxious particles or gases. More than 14 millio
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the ... company specializing in the development, manufacturing, and marketing of ... financial results for the fourth quarter and fiscal year ... Total revenue was RMB587.7 million (US$89.1 million) for ...
... board of directors of Hospira, Inc. (NYSE: HSP ... announced the election of F. Michael (Mike) Ball as the ... the board, effective March 28, 2011. Mr. Ball, 55, currently ... Begley, who will assume the role of executive chairman. ...
Cached Medicine Technology:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 12Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 2Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 3Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 4
(Date:7/11/2014)... enterprises today are shifting towards the changing trend in ... offer these global enterprises a strategic method to cut ... operational costs to companies. The aim to minimize operational ... market driver for expanding the managed services market in ... estimated to grow from $142.75 billion in 2013 to ...
(Date:7/11/2014)... 11, 2014 As reported by the ... (Weintraub 7/11/14), a significant number of severe adverse events ... issues and even death from the highly-promoted and costly ... the Times report , a regulatory filing revealed ... by patients was almost 14% of prescriptions, up from ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... Steven Reinberg HealthDay ... A potential vaccine to protect children from the worldwide scourge ... Asian children. While the vaccine only prevented dengue fever ... full series of three shots, it protected more than 88 ... dengue fever can lead to hospitalization, and sometimes death. ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... in Wheatland, CA. In the Sacramento California area there ... Train Amphitheatre can do for music fans. The venue has ... of its existence and can seat 18,500 fans each night. ... metro area) will host the “That’s My Kind of Night” ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... a key molecule that controls the growth, spread and survival ... toward new and better treatment options for pancreatic cancer . ... Beta molecule plays in pancreatic cancer and that they have ... and survival through its effect on NF Kappa B -- ...
... the drug alendronate (Fosamax) can reduce the risk of vertebral ... not osteoporosis. 3,737 postmenopausal women between ages 55 and 80 ... -2.5 were evaluated . About half the women randomly received ... thereafter while the other half took a placebo. ,The ...
... its growth factors aren’t just produced in the pancreas, but ... areas of the brain//, the result can be brain cell ... people with Alzheimer’s. ,The research was conducted in rats, ... IGF I and IGF II were produced in the nerve ...
... well known that HIV patients are at an increased risk ... study shows // aggressive antiretroviral therapy may help lower that ... antiretroviral therapy was associated with a lower incidence of Kaposi ... on more than 7,300 patients infected with HIV and the ...
... Intravenous administration of the drug tezosentan did not improve worsening ... failure // despite high hopes. The above fact was found ... to date. The study was conducted to evaluate if something ... order to speed up hospital discharge and prevent them from ...
... that how much we drink may be decided by a ... gene called DRD2 Taq1A(C32806T) polymorphism and social alcohol drinking may ... stronger gene of this type will tend to drink alcohol ... The gene is responsible for enhancing the pleasure that is ...
Cached Medicine News:
... The Perfect Single Vac Manifold ... 96-well plate in 30 minutes; ... an "open/closed" switch and a ... easy operation. contains vacuum chamber, ...
... Workstations from Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ... world today. ... ... ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
For processing mini spin columns on QIAvac 6S;...
Medicine Products: